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9ABSTRACT
A viral etiology of human breast cancer has been postulated for
decades after the identification of MMTV (Murine Mammary Tu-
mor Virus). The detection of HMTV (Human Mammary Tumor Vi-
rus) env exogenous sequences in 30-40% of invasive breast carci-
noma increased the interest towards this hypothesis. To look for
HMTV env exogenous sequences during cancer progression could
contribute to a better understanding of their role in breast cancer.
This work analyzes the presence of HMTV env exogenous se-
quences in the first phases of carcinogenesis, i.e. the pre-invasive,
as well as in metastatic lesions.
Formalin fixed and paraffin embedded samples were utilized: 20
Usual type Ductal Hyperplasia (UDH), 22 Atypical Ductal Hyper-
plasia (AH), 49 Ductal Carcinoma In Situ (DCIS), 20 Infiltrative
Ductal Carcinoma (IDC), 26 Normal Epithelial Cells (NEC) colla-
teral to DCIS or IDC, i.e. present in the same histological section,
22 primary breast cancers and their respective non metastatic lymph
nodes, 23 primary breast cancers and their metastatic lymph nodes.
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As a negative control we used reductive mammoplasties, thyroid
and colon carcinoma, and blood of healthy donors. All samples
were laser microdissected. Fluorescent nested - PCR was used to
detect the presence of HMTV env exogenous sequences. Generated
fluorescent amplicons were sized on an automatic DNA sequencer.
DNA extracted from tissues of 9 patients was analyzed by quantita-
tive RT-PCR. Moreover, we created primary cell line of human
breast cancer that was positive for HMTV env exogenous se-
quences, and then we treated the cells with 106 M Dexamethasone.
HMTV env exogenous sequences were found in 19% of NEC colla-
teral to DCIS or IDC, 27% of AH, 80% of DCIS, 35% of IDC, pri-
mary breast cancer cases that do not develop metastasis 50%, their
respective lymphocytes 36%, primary breast cancers that develop
metastasis 69.5%, and their metastatic cancer in lymph nodes
68.4%. Controls results were negative. RT-PCR and CISH con-
firmed these results. The expression of HMTV in primary breast
cancer cell line was started to increase after 16 days of treatment
with Dexamethasone. These data could contribute to understanding
the meaning of the presence of HMTV in breast carcinogenesis.
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INTRODUCTION:
Risk factors of breast cancer
Breast cancer is the second leading cause of cancer deaths in wom-
en today (after lung cancer) and is the most common cancer among
women[1]. Despite the fact that it represents the most frequent can-
cer in women and that it is largely studied all over the world since
many decades, the etiology of breast carcinoma is largely unknown.
However, the strongest risk factors for breast cancer include age,
familial and reproductive factors, lifestyle and hormonal factors
have also been linked to breast cancer risk, as well as the virus but
the data is inconsistent and inconclusive.
Age
Aging is considered as one of the greatest risk factors for the devel-
opment of new breast cancer. Breast cancer incidence is strongly
associated with an increase of age, with estimated 64% of women
over the age of 55 at the time of breast cancer diagnosis[2].
Reproductive factors
Breast cancer risk increases in women who experience late age
menopause, increasing age at first pregnancy, and low parity[3].
Menopause: Although the risk of breast cancer incidence increases
with age, postmenopausal women have a lower risk of developing
breast cancer than do premenopausal women of the same age. Each
1 year delay in the onset of menopause is associated with 3% in-
crease risk of breast cancer[4].
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Age at menarche: later age at menarche (age at 15 or more) is as-
sociated with reduction in risk of breast cancer compared to early
age (at 12 or less). 1 year delay in the onset of menarche is associ-
ated with 5% reduction in the risk of developing breast cancer in
later life [5].
Parity: increasing parity is associated with decreased risk for breast
cancer compared with nulliparity. Each birth reduces the relative
risk of breast cancer by an average of 7%. This reduction in the risk
per birth is greater in young women (before age 20 years) compared
to older ages[6].
Hormonal status
Breast cancer risk has been extensively reported in women with ex-
posure to exogenous sex steroids such as oral contraceptives (OC)
and postmenopausal hormone replacement therapy (HRT).
The hormonal effect of OC on breast cancer is complex. They often
cause protective anovulatory cycles, but the mixture of progesterone
and estrogen may also stimulate the mitotic activity on the
breast[7]. One case control study found a relative risk of 1.4 in
women who took oral contraceptives for long than 12 years com-
pared with non users. These results are consistent with the earlier
meta analysis results, which had shown no difference in risk after
10 or more years of discontinuing of oral –contraceptive use [8].
Hormone replacement therapy increase the risk of breast cancer in
current users with increasing substantial differences between the
effect of estrogen only and estrogen /progesterone preparations[9].
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Genetics
Women with a family history of breast cancer are at high risk of
developing the disease that estimated to be 5% of breast cancer
cases. The number of breast cancer genes is not yet known. How-
ever two autosomal dominant genes, BRCA1, BRCA2, which are
located on chromosome 17and 13 respectively, have been account
for most of the cases of familial breast cancer. The lifetime risk of
developing breast cancer for BRCA1 and BRCA2 mutation carriers
is 80-85%[10]. According to a combined analysis of 22 studies, the
average cumulative risk in BRCA1- mutation carried by age 70 was
65%, and 45% in BRCA2-mutation carriers [11].
Virus etiology of mammary tumor
The etiological role of the Murine Mammary Tumor Virus
(MMTV) in the development of tumors of the mammary gland in
mice is demonstrated since a long time [12]. It is interesting to note
that much of what is known about the pathogenesis of human breast
carcinoma was learned by the experimental model of the MMTV-
induced mouse mammary tumors [13, 14].
In particular, the concept of cancer progression and the recognition
of the so called preinvasive lesions as morphological steps of its
development are based on this murine model[15]. Moreover, the
promotional role of estrogens was built on the observations con-
ducted in mice [16, 17].
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These strong similarities between the human and the murine disease
represented the reason for the quest of a possible viral etiology of
breast carcinoma in women since more than half century: MMTV
viral antigens were found in human breast tumors [18] ,MMTV par-
ticles were described in human cells and milk [19, 20], MMTV se-
quences were found in humans [21].Unfortunately, these data were
never considered conclusive mainly because of their scarce repro-
ducibility. Moreover, the less sensitive and specific techniques that
used at that time are considered the main reason of the variability of
results.
Methods used in the past for viral detection
In the '70s, most of the experiments were based on immunohisto-
chemical techniques. The envelope protein of MMTV (MMTV gp-
52) was studied in human breast tumor, and in human breast cancer
cell line T47D [18], but there was conflicting results, that may be
due to low sensitive technique used.
The electron microscopy results were also conflicting. Some
laboratories report the presence of morphologically related
retrovirus particles, called RVLPs (Retrovirus-Like Particles) in
samples of human milk [22],and in macrophages of breast cancers
tissues as well as in human breast cancer cell line T47D, after
stimulation with estradiol, followed by stimulation with
progesterone [23]. Other researchers considered those particles as
cellular debris and have no correlation with the onset of breast
cancer[24].
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A subsequent wave of interest came in the early '80s, when some
laboratories reported the presence of reverse transcriptase in sam-
ples of breast cancer or in the serum of patients. An essential cha-
racteristic of retroviruses is to encode a DNA-dependent RNA po-
lymerase (called reverse transcriptase) that retrotrascripe the viral
RNA into a double helix of DNA. The enzyme reverse transcriptase
is therefore considered a marker of retroviruses and can be used as
an indicator of their presence[25]. Again, there are conflicting re-
sults obtained [20, 26], the variability in the results obtained by dif-
ferent working groups due to the low sensitivity of the techniques
used.
The same authors conclude that if the human variant of MMTV ex-
ists, it must be present in amount so low be detectable with the
techniques used. In addition, the methods discussed do not allow a
clear discrimination between the endogenous retroviral sequences
and the exogenous virus. In subsequent years it has been shown that
certain endogenous sequences (type HERV-K) are capable of pro-
ducing complete viral particles, related to MMTV[27, 28].
The molecular biology techniques significantly contributed in de-
tecting the MMTV sequences in human breast cancer.
Sequences homologous to MMTV were first shown in human DNA
by using hybridization experiments [21, 29], but there a doubt that
these sequences due to presence of endogenous retrovirus.
In 1995, Wang et al [30] selected a region of 660 bp of the MMTV
envelope gene (MMTV env), with a homology of only 16% to
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HERVK10, the prototype human endogenous retrovirus and highly
similar to MMTV. Later other authors, by using MMTV-specific
primers located in the 660 bp region, identified a MMTV envelope
gene-like sequence (MMTV env like) in 38% of a series of human
infiltrating breast carcinoma, these sequences were 90–98% homo-
logous to the MMTV env,. On the other hand, MMTV env like was
found in only 2% of normal human breast samples.
Several other groups were able to confirm these data, [31-33], whe-
reas negative results were published too [34, 35].This discrepancy
could be consequence of differences in technical procedures, of tis-
sue heterogeneity, and of the fact that env sequences are present in
few copies.
More in favor of the exogenous origin of these env-like sequences
relate to the amplification of whole proviral structure from human
breast carcinomas (figure: 1) as shown in the total homology from
the carcinomas was 95% to MMTV in 9.9 Kb and 57%to HERV-
K10 in 3.5Kb. Homology to the endogenous retrovirus was seen
primarily in the pol gene, which is known to be conserved among
different retroviruses and partially in the gag gene[36].
In 2006 Zammarchi et al [37]from this laboratory designed a rigor-
ous methodological approach able to overcome these difficulties,
based on the association of a laser microdissection procedure and a
highly sensitive fluorescent nested PCR. The MMTV env-like se-
quence was detected in 33% of a series of human breast carcinoma,
whereas normal breast tissues and other types of human tumors re-
sulted negative.
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Figure 1 Structure of proviral sequences in human breast cancer
showing genes, ORFs, and sequence homology to MMTV and
HERV-K10.
Subsequently, in 2007, Pogo et al. isolated the HMTV particles
from ascitic and pleural fluid of patient with metastatic breast can-
cer whose primary tumor where positive for env sequence and ex-
pressing env protein. They demonstrated the presence of retroviral
particles electron microscopy technique. The virus particles in cul-
ture medium showed retroviruses of type B, with size between 100
and 110 nm, a spherical shape, an eccentric dense core and the
presence of mature or immature capsid [38] (Figure: 2).
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Figure 2 Electron microscopy of MSSM3 cell associates and PF
viral particles. A and B, selected examples of cell-associated viral
particles. C and D, selected examples of viral particles in PFs. Note
that the nucleoids are condensed to varying degrees. Original mag-
nification,130,000 (bar, 0.2 Am).
Today the idea that a virus could be involved in the etiology of hu-
man breast carcinoma receives much more attention that in the past.
Several papers go towards this direction, even if in general they re-
strict their research to demonstrate viral particles and proteins in
tumor cells [38, 39].
MMTV, if really involved in breast human carcinogenesis, could
act as a promoting agent or as an etiological/pathogenetical co-
factor linked to some steps of cancer progression, such as infiltra-
tion or metastasis. To individuate where during cancer progression
MMTV exogenous sequences appear could be useful to unveil their
role in human breast cancer.
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Mouse mammary tumor virus
History:
Mouse mammary tumor virus (MMTV) was first reported in 1933
by the Jackson Memorial Laboratory and by Korteweg in 1934 as
an extrachromosomal influence on the incidence of breast cancer in
inbred mouse strains[40]. Subsequently, in 1936 Bittner showed
that a cancerous agent, which he called “milk factor”, could be
transmitted by cancerous mother young mice while nursing [41]. In
1966 it was proven that Bittner’s milk factor was virus that re-
mained dormant during the early stage of life in mouse but produce
cancer in the middle age when the sexual hormones were in right
conditions[42].
Taxonomy and Classification:
MMTV is a prototype species of the genus B retaretrovirus in the
family Retroviridae. These viruses previously were referred to as
type B retroviruses based on their appearance by electron microsco-
py (a characteristic acentric core within particles of c. 100 nm).
Multiple double-stranded DNA copies are found in the chromosom-
al DNA of most commonly used laboratory strains of mice (called
integrated or endogenous proviruses)[43].
These endogenous proviruses presumably represent viral insertions
into chromosomal DNA of germline cells and are referred to as Mtv
followed by an Arabic number, for example, Mtv8.
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Most endogenous Mtvs have defects in one or more genes and,
therefore these proviruses often fail to produce infectious virus [44]
. Currently, MMTV is classified with other betaretroviruses includ-
ing Mason–Pfizer monkey virus (MPMV), Jaagsiekte sheep retrovi-
rus (JSRV), and human endogenous retrovirus type-K (HERV-K)
[45].
Properties of the Virion:
The mature MMTV virion is100nm in diameter, contain a single-
stranded positive-sense RNA, which exists as a dimer, and is encap-
sidated as a helical ribonucleoprotein (RNP) by the nucleocapsid
(NC) protein; reverse transcriptase (RT) and integrase (IN) are
closely associated with the RNP.
The RNP is surrounded by an icosahedral shell composed of capsid
(CA) protein.
MMTV capsids are bound via the matrix (MA) protein to the viral
envelope, a portion of the cellular plasma membrane that has been
modified by the insertion of the surface (SU) and transmembrane
(TM) proteins [46] (figure: 3).
Figure 3: The structure of MMTV
Viral genome
The viral RNA is bound at either end by a short direct repeat (R) of
15 bp. The R regions are adjacent to
and 1200 bp, respectively, present at the 5 (U5) or 3 (U3)
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a regions of approximately 120
. U5: A
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unique, non-coding region which is the first part of genome to be
reversed transcribed, forming 3' of the provirus genome.
U3: A unique, non-coding region which forms the 5' of the provirus
after reverse transcription contains the promoter elements responsi-
ble for transcription of the provirus.
A cellular tRNA (tRNA3Lys) is bound through 18 bp of comple-
mentarity to each copy of the viral RNA at the primer-binding site
(PBS) located just downstream of U5.
The first splicing donor (SD) site precedes the group-specific anti-
gen (gag) region that encodes a Gag precursor. The virus also en-
codes two other precursor polypeptides, gag-pro, gag-pro-pol from
genomic RNA. Gag -pro encodes the gag proteins, a dUTPase
(DU), and the viral protease (PR). Whereas the gag-pro-pol protein
encodes RT, including a ribonuclease H (RNase H) activity and IN.
and finally the env region that encodes the envelope protein which
compose of surface (SU) and transmembrane protein (TM).
Super antigen
The long terminal repeat (LTR) of MMTV harbor an Open Reading
Frame (ORF) that encodes a superantigen (Sag), essential for
its life cycle [47]. The superantigens are different from normal anti-
gens for their ability to stimulate a greater amount of T cells, this
property derives from their ability to bind to all T cells
expressing a particular Vβ chain of T-cell receptor (TCR), and not
only to the groove formed by the α and β chains, as do antigens
conventionally. In this way, all T cells that express the chain
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Vβ, have the ability to recognize and be stimulated by
superantigens, which are presented as exogenous antigens [48].
Another characteristic of superantigens is to be present only in the
context of major histocompatibility complex molecules (MHC)
class II [49]. MMTV require functional MMTV sag to establish in-
fection of the mammary gland of mice. Laboratory experiments
have shown that exogenous virus with impaired function of Sag, are
not infectious [50]. MMTV also needs a functional immune system
(B cells, T cells) to complete its infectious cycle[51].
MMTV life cycle
The virus can be transmitted vertically (endogenous virus) when
embryonic germline cells are infected [52]but it is usually transmit-
ted horizontally through maternal milk (called exogenous virus or
milk-borne virus)[12]. MMTV particles ingested by newborn mice
in maternal milk that cross the epithelium cells through M cells in
small intestine. The virion initially encounters and infects dendritic
cells and B cells located in Peyer’s patches of gastrointestinal
tract[53]. Following virus expression, superantigen (sag) protein is
produced and presented on B cells by MHC II. The Sag binds both
MHC II on B cells and the Vβ of the T cell receptor making it a potent
T cell stimulus [54]. The stimulated T cell through sag release cyto-
kines, which cause proliferation of many B cells that subsequently,
also become infected with MMTV [55].
These infected lymphoid cells become a reservoir of MMTV that will
preserve MMTV infectivity prior to the onset of puberty in mice
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when a source of susceptible and dividing mammary cells becomes
available [50].
MMTV infection increases during lactation, where high virion pro-
duction ensures that large amounts of viral particles will increase
the probability of newborn offspring infection [56].
The chronic infection of mammary cells induces the formation of
malignant tumors, mammary adenocarcinomas. Infected T-cells
rarely become tumorigenic; though, when T-lymphocytes are trans-
formed, T-cell lymphomas do occur [57] (figure: 4 ).
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Figure 4: MMTV life cycle
Recombination of exogenous and endogenous MMTV
The coexpression of exogenous and endogenous RNA molecules in
vivo results in viral recombination. Recombination between ex-
ogenous and endogenous genomes occurs during cDNA synthesis
and is responsible for the generation of variants virus with new bio-
logical characteristics. This recombination occurs because the
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RNA-dependent DNA polymerase, reverse transcriptase, can switch
templates during replication[58].
When an exogenous MMTV infected cells where the endogenous
Mtv are highly expressed, there is a 'high possibility of recombina-
tion between two viral forms. This event generates new viruses that
have the ability to infect different strains of mice than the parental
forms.
Exogenous MMTV infects epithelial cells of mammary gland, en-
dogenous Mtv which is highly expressed in this tissue may be co-
packaged and result is a recombinant virus. If the hypervariable re-
gion of the exogenous MMTV is different from that of the endo-
genous Mtv, the recombinant viral particle is capable infecting mu-
rine strain different than the original particles of exogenous MMTV
[59].
MMTV and Tumorigenesis
MMTV does not encode any oncogene, and mammary tumorigene-
sis is therefore takes place after proviral insertion near specific cel-
lular proto-oncogene, activating them in a process called insertional
mutagenesis [60]. Retroviral integration is not sequence-specific,
therefore the greater the amount of virus, the greater probability that
the proviral DNA integrates near a proto-oncogene. In fact there has
been a considerable correlation between viral load in breast milk
and the incidence of breast cancer in a given mouse strain[61].
Once a provirus become integrated into the host genome, expres-
sion of proviral DNA is regulated by specific sequences within the
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LTR that cause increased viral transcription in response to gluco-
corticoid receptor/steroid hormone complexes. The most important
steroid hormone that increased the transcription of MMTV during
pregnancy is the progesterone [62]. Analysis of mouse mammary
tumors induced by MMTV has shown an alteration in six genes [63].
These genes belong to different family members of
fibroblast growth factor (FGF) and members of the family
Wnt gene. They are: Int-1/Wnt-1, Int-2/Fgf-3, Wnt-3, Hst/k-
Fgf/Fgf-4, Wnt-10b and FGF-8.
An interesting feature common to these genes is that they are
all involved in the short-range cellular communication, many of
them, in fact, encode secreted proteins[64]. The activation of the
expression of these genes, caused by MMTV is mainly due to the
presence of enhancer sequences in the 5 'LTR (Long Terminal Re-
peat) of the genome of MMTV. These regions act on promoters of
adjacent genes, located up to 20 kb from the LTR. The MMTV pro-
virus integrates generally outside the region coding of the proto-
oncogene and only rarely within it[65].
The Wnt genes, members of a family consist of structurally related
genes which encode secreted signaling proteins. These proteins
have been implicated in oncogenesis and in several developmental
processes, including morphology development of the tissue during
embryonic and adulthood stage[66].
The other common target for the integration of MMTV is the
gene family of fibroblast growth factor (FGF). The proteins en-
coded by these genes are potent angiogenic factors in vivo, and
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ivolve in cell differentiation [67]. Three of the eight members of
the FGF family, namely, Int-2 (FGF-3), FGF-4 and FGF-8, are acti-
vated by the insertion of proviral MMTV. As in the case of genes
Wnt-1 and Wnt-3, the three FGF genes are not normally expressed
in the mammary gland, but are found only or in embryonic life or in
adult tissues other than breast [68, 69]. It has been shown that the
onset of murine breast cancer is associated with activation of tar-
geted genes (int-2 (Fgf-3), hst (Fgf-4), and Fgf-8) by MMTV pro-
viral insertion. These observations suggest therefore that different
genes cooperate in tumorigenesis [70].
Replication cycle of MMTV
MMTV replication cycle begin when the viral surface glycoprotein
,gp 52 bind to tranferrin receptor (tfr1) that expressed in many ro-
dent cells. Human tfr1 is failed to allow viral entry, however use of
MMTV bound to the trf 1 enters the cell via endocytosis of clathrin-
coated pits, and receptors are recycled to the cell surface where they
allow entry of additional MMTV particles into previously infected
cells.
Following entry and partial uncoating in the cytoplasm, the virally
encoded RT is activated. PBS, the primer binding sequence of viral
RNA is complementary to the 3’ nucleotides of the host tRNA. The
host tRNA, lys-3 acts as the DNA primer for the reverse transcrip-
tase to synthesize minus-strand proviral DNA.
The initial product of reverse transcription is an RNA-DNA com-
plex. The RNase H digests the RNA strand, and allows the synthe-
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sis of double-stranded provirus[71]. However, the product of re-
verse transcription is different from the starting template so that the
U5 and U3 sequences present uniquely in viral RNA are duplicated
to give longer repeats at each end of the provirus (LTRs).
Because nuclear entry of the preintegration complex containing the
provirus is thought to require nuclear envelope breakdown during
mitosis, it is generally believed that MMTV must infect dividing
cells. Once the preintegration complex enters the nucleus the viral
integrase randomly inserts the provirus into the host genome[72].
Integrase introduces an asymmetric cut 2 bp (cytosine, and adenine)
from the linear ends of the provirus as well as an asymmetric break
exactly 6 bp apart on opposite DNA strands of host DNA. Proviral
integrations are not site-specific and may occur at transcriptionally
active sites. Following the joining reaction, the repair of virus–cell
junctions by cellular enzymes generates a 6 bp direct repeat of cell
DNA that flanks the viral LTRs[73].
The integrated MMTV LTR is a stretch of DNA (1195 base pairs in
length) at the 5’ end of the viral genome that is responsible for the
expression of the virus in mammary epithelial cells and for the acti-
vation of cellular proto oncogenes.
Transcription is initiated from the standard promoter in the 5' LTR
starting at the U3/R junction and terminating at the R/U5 junction.
Transcription of the MMTV LTR produces full- length mRNA,
spliced mRNAs, as well The spliced mRNAs are the env mRNAs
and the sag mRNAs [74, 75] .MMTV also produces a doubly
spliced mRNA that encodes the RNA export protein, Rem[76]. In
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most cell types, the levels of gag-pol and env mRNAs greatly ex-
ceed sag and rem mRNAs.
The viral mRNAs are translated into the viral proteins in the cytop-
lasm using the host cellular machinery. The gag mRNA is trans-
lated into the precursor protein Pr77, a Gag polyprotein. Proteolytic
processing of Pr 77 by the viral protease produces the structural
proteins: the matrix protein p10 or MA; the capsid protein p27 or
CA; the nucleocapsid protein p14 or NC, and some smaller proteins
p21, p3, and p8 that have no known function [77, 78]. Though, p21
is cleaved into a few smaller proteins[79].
Capsid protein forms the structural shell of the core of the virion,
which enclose the ribonucleoprotein comple that contains the genomic
RNA. The capsid protein appears to be important in the assembly of
immature capsid [80].
The nucleocapsid protein has a sequence that includes many basic
amino acids and a cysteine-histidine box that is similar to a zinc finger
domain seen in DNA-binding proteins, which explain its packaging
role of the viral RNA in the cytoplasm[81].
The gag-pro mRNA is translated as a precursor protein Pr 110, a
Gag-Pro polyprotein. Within Pr 110, the NC sequence of the gag
gene and the first part of the pro gene comprise a dut gene, which
encodes DU a dUTPase. DU prevents misincorporation of uracil
and mutation of newly synthesized proviruses in nondividing
cells[82].
The C terminus end of the pro gene codes for p13 or PR the viral
protease. PR is responsible for the cleavage events that produce the
31
mature virion proteins, MA, p21, p3, p8, CA, and NC, the functions
of p21, p3, and p8 are currently unknown[83]. The precursor pro-
tein Pr160, a Gag-Pro-Pol polyprotein encodes a viral reverse tran-
scriptase with RNase H activity and an integrase[84].
The env mRNA is translated into a precursor protein, pr73 env on
membrane bounded polyribosomes. This precursor is modified by
glycosylation in both the endoplasmic reticulum and the Golgi,
where a cellular protease cleaves the Env poly protein to produce
gp52, SU a viral surface envelope protein and gp36, TM a viral
transmembrane envelope protein. SU and TM remain attached to
each other via disulfide bonds[85]. They travel to the host plasma
membrane in vesicles and are then incorporated into the lipid
envelope of the mature B type virion when the immature A particle
buds from the host cell[86].
The sag mRNA is translated into a precursor protein Pr 48, SAg, a
superantigen protein. This protein is glycosylated and cleaved in the
Golgi by protease to generate SAg protein[87]. Sag is associated
with major histocompatibility complex (MHC) class II protein at
the surface of antigen-presenting cell. Sag is essential activation of
certain T cell subsets containing Vβ TcR [88].
MMTV utilizes a polyprotein strategy for viral assembly. This
process insures that none of the individual proteins: matrix, capsid,
and nucleocapsid, are individually targeted to the membrane. The
order of the proteins in the polyproteins corresponds to their rela-
tive location in the virion from the outside of the virus to the inside
of the virus.
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MMTV polyproteins assemble into a capsid shell or imma-
ture A particle in the cytoplasm. The formation of the A particle
occurs prior to its transport to the plasma membrane[86],then the
immature A particles bud from the tips of long filamentous actin
projections as mature virions [89]. The viral envelope proteins are
transported to the plasma membrane via the host secretory path-
way. The A particles associate with the cell membrane, they ac-
quire a viral lipid envelope with viral envelope proteins as the virus
buds from the host cell. [90].
The budding process of MMTV seems to involve the host actin cy-
toskeleton. The immature viral A particles have been observed at the
tips of long filamentous projections [86].In addition, cytochalasin
D, which disrupts the actin cytoskeleton, reduced the number of
mature viral B particles released into the supernatant by 80%
[91]Thus budding of MMTV appears to be an actin-dependent
process. Infected human breast cells with MMTV initiated the forma-
tion of filamentous projections with virus particles at their tips.
These filopodial projections emerged from the cell surface of in-
fected live cells when viral production was hormonally induced with
dexamethasone[92].
Human endogenous retrovirus:
Human endogenous retroviral (HERV) elements comprise 8% of
human DNA [93], and are likely to be derived from ancient viral
infections during evolution but their biological relevance is largely
unknown.
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It is thought that exogenous infection allowing HERVs sequences to
be inserted into the genome of germ line cells, where they have
been replicated along with the host's cellular genes following a
Mendelian pattern [94] and[95]. Integration of endogenous retrovi-
ruses into the human germ line is thought to have occurred 2 to
about 70 million years ago depending on the individual retroviruses
and were introduced by mechanisms involving reverse transcrip-
tion. Most of human endogenous retroviruses (HERVs) are defec-
tive, due to multiple mutations or deletions, and are therefore none
of them is capable of encoding complete viral particles and cause
infection [96]. Although many HERVs are transcriptional active,
they are not able to produce functional proteins. The high number
of copies present in the human genome is attributed to repeated
cycles of infection and retrotransposition [97].
Classification
The known HERVs families have been grouped into classes.
HERV class I shows clustering phylgenetically with Gammaretro-
virus, those clustering with the betaretrovirus are class II, and class
III HERV clustering with spumaviruses [98].
HERV families that reside in human genome are estimated to be
between 30 and 50[99], among them various so-called HERV-K
families. The letter K indicates that a primer binding site specific
for lysine-tRNA was used to prime reverse transcription. In total, 10
HERV-K families have been defined based on sequence similari-
ties, and they have been named HERV-K(HML-1) to HERV-
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K(HML-10) (for human MMTV [mouse mammary tumor virus]-
like) because of some sequence relationship to the mouse mammary
tumor virus [100].
The biological function of HERV
The distribution of endogenous retroviral sequences, scattered
throughout the genome of mammals, suggests that they have impor-
tant biological functions and therefore have been conserved during
evolution. Using reverse transcription and subsequent insertion of
their genome into the host DNA, these sequences regulate the plas-
ticity of genome, accelerating the evolution of new genes and alter-
ing the transcription of existing genes [101].
Their biological function is still unknown and there are many as-
sumptions that, to date, are proposed. In analogy with animal mod-
el, it has been hypothesized that these endogenous retroviral se-
quences are protected in respect of their endogenous counterparts.
In the case of MMTV, for example, the expression of endogenous
Sag coding sequences during the formation of the immune system,
induces clonal deletion of all T cells reactive to that particular Sag
and at the same time, makes it immune to the forms of MMTV ex-
ogenous coding Sag with the same specificity to T cells [50, 102].
There are several experimental evidences that show the possibility
of recombination between exogenous viruses and endogenous re-
troviral sequences. It has been identified a variant of MMTV, high-
ly tumorigenic, resulting from recombination between sequences
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derived from endogenous Mtv, and a strain of exogenous MMTV
[59].
HERV-K family
Unlike the majority of HERV, the family of HERV-K has genes an
open reading frame (ORF) for essential genes of retroviruses (gag,
pol and env) as well as its ability to synthesize all essential retrovir-
al proteins [103, 104]. This family was originally identified for its
high homology with the Mouse Mammary Tumor Virus (hence the
nomenclature further HML, human endogenous MMTV-like). The
HERV-K are present in the human genome with about 30-50 pro-
viral copies and approximately 10,000 LTRS solitary, arising, prob-
ably by homologous recombination between LTRS, followed by
excision of the viral genome intermediate[102].
HERV-K families have been classified into six subgroups (HML by
HML-1 to-6), based on sequence homology in the conserved region
of the pol gene, encoding the enzyme reverse transcriptase [105,
106]. HERV-K10 has been sequenced and showed to have a com-
plete provirus of 9 Kb, and contains ORFs for all retroviral genes,
but showed to have a stop codon in the env gene and a frameshift in
the gene gag[107].
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MATERIALS AND METHODS
Specimens
All tissues, formalin fixed and paraffin embedded, were collected
and archived (2005-2009) at the Division of Surgical, Molecular
and Ultrastructural Pathology, University of Pisa.
We have collected 91 paraffin embedded tissue cases of ductal car-
cinoma insitu (DCIS) and invasive ductal carcinoma (IDC), as well
as usual ductal hyperplasia (UDH) Atypical ductal hyperplasia
(ADH). 49 of samples were DCIS, 20 samples of them have also
IDC. It was possible to collect 26 samples of normal epithelial cells
(NEC) collateral to DCIS or IDC (c-NEC) (figure: 5).
We have collected 22 samples of primary breast cancer and their
respective non metastatic lymph nodes in order to study the HMTV
status in the primary tumor and their respective non metastatic
lymph nodes. Moreover, we have collected also 23 samples of pri-
mary breast cancer and their respective metastatic lymph nodes to
compare the HMTV status in non metastatic compared to metastat-
ic lymph nodes (figure: 6). As negative control were used: 20 NEC
from reduction mammoplasty (nc-NEC); 6 papillary thyroid carci-
noma; 6 colon adenocarcinoma, and DNA extracted from 6 healthy
blood donors. DNA of a mouse infected by MMTV was the positive
control. Of the DCIS, 15 were poorly differentiated, 33 moderately
differentiated and 1 well differentiated.
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Figure 5: The histological types, and the number of breast cases (benign and
malignant) and negative controls.
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DCIS present in 1 or more ducts or in an aggregate not exceeding
0.2 cm. DCIS can be of high, intermediate, or low grade: a) pleo-
morphic large cells with abundant mitoses and with variable archi-
tecture, often solid and with a central necrotic debris; b) uniform
cells, with small nuclei and frequently with a cribriform or mi-
cropapillary configuration; c) the neoplastic nuclei show pleomor-
phism of a degree between high and low grade DCIS, (figure: 7).
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Laser microdissection
A Leica ASLMD automatic laser microdissector was used to select
the epithelial cell population to be studied (Figure: 8). Three µm
thick sections were cut from each case using each time a new mi-
crotome blade, and applied on microdissecting slide, followed by
staining with haematoxylin and eosin, then obtaining a total of
10,000–15,000 cells (figure:9). Stromal and inflammatory cells
were carefully excluded. Due to the long experience of the labora-
tory with this method, no difficulty was found in selecting areas of
interest.
Figure 8: Laser capture microdissector
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DNA extraction from paraffin embedded tissue
We have used the QIAamp DNA FFPE Tissue Kit for purification
of DNA from FFPE tissue sections.
1. Cut 2 sections of 10 µm thick, using sterile forceps and
blade for each sample, place it in sterile 1.5ml eppendorf
tube
2. Add 180 µl Buffer ATL, and 20 µl proteinase K, and mix by
vortexing.
3. Incubate overnight at 56oC
4. Briefly centrifuge the 1.5 ml tube to remove drops from the
inside of the lid.
5. Add 200 µl Buffer AL to the sample, and mix thoroughly by
vortexing. Then add 200 µl of ethanol (96–100%), and mix
again thoroughly by vortexing.
6. Briefly centrifuge the 1.5 ml tube to remove drops from the
inside of the lid.
7. Carefully transfer the entire lysate to the QIAamp MinElute
column (in a 2 ml collection tube), and centrifuge at 6000 x
g (8000 rpm) for 1 min. Place the QIAamp MinElute col-
umn in a clean 2 ml collection tube, and discard the collec-
tion tube containing the flow-through.
8. Carefully open the QIAamp MinElute column and add 500
µl Buffer AW1 without wetting the rim. Close the lid and
centrifuge at 6000 x g (8000 rpm) for 1 min, then discard the
collection tube containing the flow-through.
44
9. Carefully open the QIAamp MinElute column and add 500
µl Buffer AW2 without wetting the rim. Close the lid and
centrifuge at 6000 x g (8000 rpm) for 1 min, then discard the
collection tube containing the flow-through.
10. Centrifuge at full speed (20,000 x g; 14,000 rpm) for 3 min
to dry the membrane completely.
11. Place the QIAamp MinElute column in a clean 1.5 ml mi-
crocentrifuge tube and discard the collection tube containing
the flow-through. Carefully open the lid of the QIAamp Mi-
nElute column and apply 50 µl Buffer ATE to the center of
the membrane.
12. Close the lid and incubate at room temperature (15–25°C)
for 1 min. Centrifuge at full speed (20,000 x g; 14,000 rpm)
for 1 min.
RNA extraction from cell culture
We have obtained cell pellet from primary tissue culture of breast
cancer after the first subculture for RNA extraction in order to study
the gene expression of the HMTV. RNA extraction was performed
using Using Qiagen’s RNA Mini Kit.
1. Harvest cells according to standard tissue culture procedures
to obtain a cell pellet, divide the pellet into two separate 15
ml tubes.
2. To the cell pellet in each tube, add 600ul of Buffer RLT
containing 6 µl B-Mercaptoethanol.
45
3. Vortex the pellet to disrupt it as much as possible, then
transfer the lysate to QiaShredder columns, and Centrifuge
at maximum speed for 2 minutes to fully homogenize the
cells.
4. Add 600ul of 70% Ethanol to each tube of the homogenized
cells and mix well, Pipet 600ul of the sample in each tube
onto RNeasy mini columns.
5. Centrifuge at 11,000rpm for 30 seconds. Discard the flow.
6. Add 700ul of Buffer RW1 to the columns, centrifuge at
11,000rpm for 30 seconds then discard the flow.
7. Add 500ul of buffer RPE to the columns, Centrifuge at
11,000rpm for 30 seconds, and then discard the flow.
8. Add another 500ul of Buffer RPE to the columns, centrifuge
at 11,000rpm for 2 minutes then discard the flow.
9. Transfer the RNeasy columns into fresh 1.5mL nucleic acid
free tubes.
10. Add 30ul of RNase free water directly onto the columns,
centrifuge at 11,000rpm for 1 minute.
11. Quantitate the RNA on the nanodrop, keep it at -70 oC.
cDNA synthesis:
We have used fermantas cDNA synthesis kit to synthesis cDNA
using RNA extracted from cell culture as a template.
1. Add 0.5-1µg of RNA into sterile nuclease-free tube on ice.
2. Add also 1µl hexamer primer
3. Make the total volume 12µl by adding nuclease-free water.
46
4. Add the following in the indicated order
 4µl of 5x reaction buffer
 1 µl of Ribolock 10 RNase inhibitor (20u/ µl)
 2 µl of mM dNTP mix
 1 µl of RevertAID M-MuLV reverse transcriptase
(200u/ µl).
5. Mix gently and centrifuge, then incubate for 5min at 25 oC.
followed by 60 minutes at 42 oC.
6. Terminate the reaction by heating at 70 oC for 5 minutes.
The synthesized cDNA can be used immediately or store at -20 oC
for less than a week. For longer storage, -70 oC is recommended.
DNA amplification suitability
DNA was checked for the absence of PCR inhibitors by amplifying
HERV-K10, β actin provirus target templates. Primers used for tar-
gete amplifications are in table: 1. Cycle conditions were: 1 cycle,
94 °C, 10 min; 30 cycles, 94 °C, 30 s; 50 °C, 30 s; 72°C, 45 s; final
extension, 72 °C, 7 min in 30 μl reaction mixture containing 1×
PCR Buffer (500 mM KCl, 150 mM Tris-HCl, pH 8.0), 1.5 mM
MgCl2, 200 μM each deoxynucleotidetriphosphates, 0.5 μM of for-
ward and reverse primer and 2.5 U AmpliTaq Gold (Applied Bio-
systems, Foster City, CA, USA). DNA samples were considered
free of PCR inhibitors if HERV-K10, β actin amplicons were clearly
visible on a 1.8% agarose gel.
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PRIMERS SEQUENCE (3/-5/)
HERV-K10 5/ CCACGGGTAAATTTACA
HERV-K10 3/ TATTTTTGGTCTTGGGGTAG
β-actin 5/ CTTCTGCCGTTTTCCGTAGG
β- actin 3/ TGGGATGGGGAGTCTGTTCA
ENV 5/ GATGGTATGAAGCAGGATGG
ENV 3/ CCTTTTCTCTATATCTATTAG
ENV3/- nested AAGGGTAAGTAACACGGGTCATGTA
ENV5L CCAGATCGCCTTTAAGAAGG
ENVLTR 3 CGAACAGACACAAACACACG
Table 1: Primer sequences
HMTV sequence detection
Fluorescent nested-PCR was used to detect the presence of the
HMTV env-like sequence. Generated fluorescent amplicons were
sized on an automatic DNA sequencer. The pairs of primer were
designed on the bases of the sequence available in GenBank (Ac-
cession No. AF243039). Slight changes were introduced in the pro-
cedure previously used by ourselves [37] to adapt it to paraffin em-
bedded tissues. They consisted mainly in decreasing the length of
the amplicons to a maximum of 250bp. The outer primers yield a
248 bp fragment from nucleotide [nt] positions 231–480 of MMTV-
like env, the inner primers yield a 202 bp fragment (nt positions 231
and 431). Sequences of the outer primers for the first PCR were:
Forward: 5/gatggtatgaagcaggatgg3/ and Reverse: 5/ cctcttttctctatatc-
tattag3/ and for the nested PCR the forward primer sequence was
48
the same as the above while the reverse was Reverse Nested-
5/aagggtaagtaacacaggcagatgta3/. Both PCRs were carried out in 50
μl containing 1× standard PCR buffer, 1.5 mm MgCl2, 200 μm each
dNTP, 0.5 m unlabelled reverse primer (MWG Biotech), 0.5 μm 6-
FAM-labelled forward primer (Applied Biosystems, Milan, Italy)
and 2.5 U AmpliTaq Gold (Applied Biosystems). Input target tem-
plate was 500 ng genomic DNA in the first round PCR and 2 μl of
first round PCR in the second, respectively. Amplification profile
was as follows: 1 cycle 94 ◦C, 10 min; 40 (first round) and 30 (sec-
ond round) cycles at 94 °C, 45 s; 58 °C, 45 s; 72 °C, 60 s; final ex-
tension, 72 °C, 7 min. To prevent PCR contamination, water con-
trols and negative DNA samples were included every five samples
in each run. Fluorescent amplicons were analysed by capillary elec-
trophoresis and appeared as peaks in an electropherogram (figure:
10). Amplicon size was extrapolated from a molecular size ladder
re-suspended in PCR buffer and run in parallel. Briefly, 3 μl PCR
products from both amplification rounds were mixed with 0.5 μl
ROXlabelled size standard (Gene Scan 400 HD ROX; Applied Bio-
systems) and 11.5 μl formamide (Hi-Di Formamide, Applied Bio-
systems). After denaturation at 95 °C for 3 min, samples were
loaded onto an ABI PRISM 3100 automatic genetic analyser and
analysed using GENESCAN software, version 3.1 (Applied Biosys-
tems).
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Figure 10: Fluorescent capillary electrophoresis, A: first PCR, B:
nested PCR
Sequencing of HMTV env PCR fragments
HMTV env PCR fragments were purified using Multi Screen PCR
Plates (Millipore) following this protocol:
 Dilute PCR by adding 70 µl of water. Mix gently by pipet-
ing up and down 3-5 times.
 Transfer diluted reactions into the bottom of the plate
wells.
 Place the plate on the vacuum manifold.
 Set the vacuum to 23-25” Hg.
 Apply vacuum until the solution has been completely re-
moved from the wells.
 Shut off the vacuum source and blot the excess liquid from
the bottom of the plate.
 Add 100 µl of water and shake for 2 minutes on a micro-
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plate shaker.
 Apply vacuum until the solution has been complete-
ly removed from the wells.
 Shut off the vacuum source and blot the excess liquid from
the bottom of the plate.
 Resuspend the purified sequencing products in 25 µl of
water by shaking for 10 minutes on a microplate shaker.
 Transfer the purified sequencing products to an appropriate
plate
Then we performed Cycle Sequencing reaction using Big-
Dye Terminator kit v3.1 (Applied Biosystems) and 2,5 pmol/µl
of each primer, for a final volume of 20 µl. We used these condi-
tions: 96 °C using the QIAquick Gel Extraction kit (Qiagen) and
sequenced on an ABI PRISM 3130XL (Applied Biosystems). Each
sequence was aligned by using BLAST search function
(http://blast.ncbi.nlm.nih.gov) to MMTV sequences deposited in
GenBank.
HMTV Real Time PCR assay
Extracted DNA from 9 patients was analysed by quantitative RT-
PCR: in 2 patients NEC, DCIS and IDC were available, whereas in
the other 7 cases DCIS and IDC only. Briefly, 25μl PCR reaction
mixture was prepared using 2X Master Mix (MesaGreeen qPCR,
Eurogentec, San Diego, CA), 0.5 μl of HMTV primer (0.3uM) for
the ENV region (nested PCR 202bp). The viral load was determined
as the mean of triplicate sample values. GAPDH which is a single
copy gene was used as an internal reference control. Four ten-fold
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dilutions (1X101–104 copies/ml) of genomic human DNA (GAPDH
gene) and of HMTV env amplicons were included as standard
curves on each run. HMTV env-like and corresponding GAPDH. A
HMTV positive control DNA extracted from a mouse known to be
infected with the virus and a template negative control (PCR mix
only) were also included in each PCR run. PCR were run on the Ro-
tor-Gene Q from Qiagen (figure 11). The standard curves were
plotted by the Rotor-Gene software detector system printing the Ct
values against each known concentration of standards (HMTV or
GAPDH sequence) and MMTV copy number per DNA sample was
calculated by the detector.
Figure 11: Rotor gene real
Amplification of the probe (2.7 kb env
We have prepared homemade probe of
Amplification of 2.7kb env
kit, the 50 μl reaction contains 3 units
fer, 2 μl of 50 mM mgcl2, 8 μl of 2.5 mM dNTP, 0.2μm of each
primer (5L, LTR3)
was incubated at 94 for 2 minutes, 94 for5 seconds 68 for 5minutes
for 40 cycles.
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time PCR
-LTR)
HMTV env-LTR 2.7kb.
-LTR was achieved using takara EX taq
of enzyme, 5 μl 10xPCR bu
[36], 1μg of mouse DNA positive for HMTV
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Labeling the probe
The band at 2.7kb was cut and purified using centri-sep kit (applied
biosystem), then sequenced to make sure it’s the true target.
Labeling probe was done using DIG-NICK translation mix kit
(Roche) as the following:
1. Add 1 µg the purified PCR product to sterile, double distill-
ed water and end up with a final volume of 16 μl.
2. Add 4 μl DIG-Nick Translation Mix, mix and centrifuge
briefly.
3. Incubate for 90 min at 15°C, and then place the reaction on
ice.
4. Take a 3 μl aliquot per 20 μl reaction volume from the reac-
tion, add gel loading buffer, denature it at 95°C for 3 min,
put it on ice for 3 min and run the sample on an agarose mi-
nigel along with a DNA molecular weight marker. The
probe should range between 200 and 500 nucleotides in
length.
5. If necessary reincubate the reaction at 15°C and check the
fragment size again.
6. When correct probe length is achieved stop the reaction by
adding 1 μl 0.5 M EDTA (pH 8.0) per 20 μl reaction volume
and heating to 65°C for 10 min.
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Chromogen in situ hybridization (CISH)
Sections were cut at 4 μm thicknesses, mounted onto positively
charged microscope slides, and left to dry overnight at 37°C. Sec-
tions were then deparaffinized and rehydrated. Antigen retrieval
was achieved by heat retrieval using water bath (DAKO). The
slides were placed in Coplin jars containing enough 0.01 M sodium
citrate solution (pH 6.0) to cover the sections, and then incubate in
water bath at 80°C for 30 minutes. In order to expose the nuclear
components, proteinase K was applied on the sections for 10 mi-
nutes at 37°C. The hybridization solution is prepared just before
applying, for each slide make up to 10 µl of the solution of the
probe (50 ng) in hybridization solution (2x SSC, 50% formamide,
10% dextran sulfate). The section then dehydrated using absolute
ethanol, followed by adding up to 10µl of probe with hybridization
solution on tissue, then apply cover slip over the probe solution and
avoid bubbles formation, after that seal the edge of cover slip with
cement material. Denaturation and hybridization were achieved by
incubate the slide for 5minutes at 80°C and 16 hours at 37 °C re-
spectively using thermobrite (ABBOTT hybridizer). The day after
get the slide out of the hybridizer, remove the cover slip and wash
with 0.5 x SSC at 75oC for 30 seconds, followed by incubation in
2x SSC at room temperature. the results were detected by applying
anti-digoxigenin-AP conjugate for 30 minutes at 37 °C, that pro-
duce a characteristic nuclear black stain after 5-20 minutes of ap-
plying NBT/BCIP substrate (figure: 12).
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also prepared. The positive control slides were prepared from a case
known to be positive for HMTV env in PCR study. The negative
control slides were prepared from the same tissue block, but incu-
bated with hybridization buffer instead of the HMTV env probe.
4-5µm
Stringent Wash Hybrit
Tissue preparation
Block Step
Mouse Anti-DIG
NBT-CIP
Color formation
Figure 12: CISH protocol
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Tissue culture
We have prepared the media needed for primary breast cancer tis-
sue cultures as the following:
Collecting medium
DMEM F12 with 200U/ml penicillin, 200 µg/ml streptomycin, 5
µg/ml fungizone.
Primary culture medium:
DMEM F12 supplemented with
1. 0.5µg/ml hydrocortisone
2. 5µg/ml insulin
3. 20 ng/ml EGFR
4. 200 µg/ml cholera toxin
5. 0.004M/ml bovine pituitary extract
6. B27 2%
Complete culture medium
DMEM F 12 containing 10% heat-inactivated fetal bovine serum
albumin (HIFBS).
Antibiotic solution (ABC-PBSA)
1. Phosphate buffered saline (PBSA)
2. 200 U/ml penicillin
3. 200 µg/ml streptomycin
4. 5µg/ml fungizone
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Day 1 protocol
1. Preparing the hood by ensuring that it’s clear and swabbing
it by 70% alcohol.
2. Brings the reagents and materials necessary for the proce-
dure, swab bottles with 70% alcohol and place items re-
quired immediately in the hood.
3. Obtain breast tumor biopsies from pathology and transport
to the laboratory in colleting medium. If the tissue cannot be
processed immediately (recommended),it may be stored re-
frigerated for up to 24 h without significant loss of viability
4. Wash tissue extensively with phosphate buffered saline
lacking Ca2+ and Mg2+ (PBSA) supplemented with
200U/ml penicillin, 200 µg/ml streptomycin, 5 µg/ml
fungizone (ABS-PBSA)
5. Minced finely by using crossed scalpels in a sterile Petri
dish.
6. Wash twice in ABS-PBSA.
7. Disaggregate for 18-20 h in 200 U/ml collagenase A (made
up in complete culture medium) in a 37C incubator (either
in multiwell plate, or Petri dish)
8. Remove tissue from incubator, and shake vigorously by
hand. This will break up any remaining large clumps of par-
tially digested tissue
9. If there still undigested tissue re incubate the tissue with
fresh medium and collagenase 200U/ml.
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Day 2 protocol
1. Transfer the Petri dish contents to 50 ml sterile centrifuge
tube, close the cap and wrap it with parafilm.
2. Spin at1200g for 5 minutes.
3. Culture the pellet in the primary cultured medium using
primary culture flask (blue cap); incubate the flask at 37oC
and 5% Co2.
4. The day after change the medium to get rid of unattached
cells in case of attached conditions, after that change the
medium every 2 days.
5. For floating cell culture, incubate the cells in
Subculture
The need to subculture implies that cells in the primary culture have
increased to become 70-80% confluent.
1. Take the culture flask to the sterile working area under the
hood, then remove and discard the medium
2. Add PBSA/EDTA prewash (0.2ml/cm2) to the side of the
flask opposite the cells to avoid dislodging cells.
3. Add trypsin (0.1ml/cm2) to the side of the side of the flasks
opposites the cells. Turn the flask over and lay them down.
Ensure that the monolayer is completely covered.
4. Incubate at room temperature (5-10 min), with the flasks ly-
ing flat, until the cells round up; when the flask is tilted the
59
monolayer should slide down the surface. Don’t leave the
flask longer than necessary.
5. Add complete culture medium (0.1-0.2ml/ cm2), and dis-
persed the cells by repeated pipetting over the surface bear-
ing the monolayer.
6. Finally, pipette the cell suspension up and down for a few
times, with the tip of the pipette resting on the bottom corner
of the flask, taking care not to create foam.
7. Count the cells with hemocytometer; dilute the cell suspen-
sions to appropriate seeding concentration, by adding ap-
propriate volume of cell suspension to a premeasured vol-
ume of medium in a culture flask, and incubate the flasks at
37oC and 5% Co2.
Removal of fibroblastic cells from the tissue culture
We have used Anti-fibroblast microbeads form MACS to get rid of
the fibroblast from tissue culture.
1. Trypsinized the cells as mentioned above, and determine
the cell number.
2. Centrifuge cells at 300xg for 10 minutes. Aspirate super-
natant completely.
3. Resuspend cell pellet in 80 µl of buffer per 107 total cells.
60
4. Add 20 µl of Anti- fibroblast Microbeads per 107 total
cells.
5. Mix well and incubate for 10 minutes in the refrigerator
(2-8oC).
6. Washing cells by adding 1-2 ml of buffer 107 cells and
centrifuge cells at 300xg for 10 minutes. Aspirate super-
natant completely.
7. Resuspend in 500 µl buffer.
8. Prepare the magnetic field and the adaptor, then apply the
column and prime it with PBS.
9. Apply a sterile collecting tube under the applied column,
then add the labelled cells to be separated to the column
and collect the negatively selected cells ( fibroblast con-
fined in the column)
10. The negatively selected cells (no fibroblast) then sub
cultured.
Cryopreservation the cells
Grow the culture to late log phase; prepare a high concentration of
cell suspension by:
1. Trypsinize monolayer and resuspend cells in medium at 1-
10x1010/ml
2. Add cryoprotectant, dimethyl sulfoxide (DMSO) to 10% v/v
3. Divide cells in a prelabelled polypropylene plastic ampoules
4. Clip the ampoules on to an aluminium cane, insert in a card-
board tube and transfer to a -70 oC.
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Statistical analysis
One way Anova test was used to statistically evaluate the differ-
ences in viral copy numbers between the early and later stages of
tumour progression in the same patient.
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RESULTS
HMTV frequency in phases of breast cancer progression
The presence and the frequency of HMTV env sequence in normal
breast and in all phases of breast cancer progression are described
below and reported in Table 2 and in Figure 13.
Normal epithelial cells: a) exogenous HMTV env sequences were
found in 19, 2% (5 out of 26) of NEC collateral to DCIS or IDC. b)
the 20 cases of normal breast samples obtained by reductive mam-
moplasty were result all negative (c and nc stand for collateral and
non collateral respectively, Figure.13)
Ductal epithelial hyperplasia: a) the 20 cases of UDH resulted all
negative. b) exogenous HMTV env sequences were found in 27% (6
out of 22) samples of AH.
Breast carcinoma: a) exogenous HMTV env sequences were found
in 79.6% (39 out of 49) of samples of DCIS. The presence of the
virus was not related to the presence of the preinvasive lesion in the
same histological section hosting an infiltrating carcinoma. b) 35%
(7 out of 20) of samples of IDC resulted positive.
Controls: all the 6 cases of infiltrating papillary thyroid carcinoma,
the 6 cases of colon adenocarcinoma and the 6 cases of DNA from
blood of healthy donors were negative.
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Figure 13: The frequency of HMTV env sequence in normal breast
cells and all phases of breast cancer progression.
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Tissue Cases HMTV env
positivity
%
Ductal Carcinoma In Situ 49 39 79.6
Invasive Ductal Carcinoma from cases with
DCIS
20 7 35
Normal ducts from cases with DCIS 26 5 19
Usual Type Hyperplasia 20 0 0
Atypical Hyperplasia 22 6 27
Normal ducts from plastic breast reductions 20 0 0
Papillary Thyroid carcinoma 6 0 0
Colon Adenocarcinoma 6 0 0
Healthy blood donors 6 0 0
Table 2: Number of cases tested with different histological types
and number of HMTV env positive cases found in all phases of
breast cancer progression.
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Different histological structures obtained from the same patient: in
14 patients with DCIS positive for HMTV env-like se-
quences, normal breast and IDC were also available; in one case all
the three samples resulted positive (case 1) , in 4 cases both DCIS
and IDC were positive (cases 6-9), whereas the normal structures
negative; in 3 cases normal structures and DCIS were positive, and
IDC negative (cases 2-4); in 6 cases only DCIS were positive (cases
12-17). In the 6 patients with DCIS negative for HMTV env-like
sequences in which normal structures and/or IDC were also avail-
able also the last two resulted negative (cases 41-46). Of four cases
of positive DCIS in which IDC were available, the last one was
positive in 2 and negative in 2 (cases 10-11 and 26-27).
In 9 cases of positive DCIS in which only normal gland structures
were also available, 8 of the last ones resulted negative and 1 posi-
tive (cases 18-25 and 5). In the 16 cases with only DCIS available,
13 were found positive and 3 negative (cases 28-40 and 47-49).
Sequence detection
To determine whether the amplified fragments were indeed homo-
logous to HMTV, the 248 bp amplicons that showed clear band on
agarose gel (Figure: 14) were sequenced, aligned to the correspond-
ing region of the prototype MMTV sequence and MMTV (Gen-
Bank Accession Nos AY152 721 and AF243039, respectively).
Multiple nucleotide alignment showed 97% homology to both
MMTV and HTMV (Human MTV) env sequences. Finally, no sig-
nificant hits were found when the 2 sequences were compared to the
human genome sequences available in GenBank, indicating that
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these amplicons were not of human genomic or endogenous retrovi-
rus origin.
248 bp
Figure 14: Amplification of 248 bp HMTV env gene by PCR, 2%
agarose gel electrophoresis.
HMTV viral load with RT-PCR
Real time PCR was conducted on DNA extracted from DCIS and
IDC from 7 different patients. GAPDH was used as the internal
gene reference control, so each bar represents the ratio between
HMTV DNA copy number and GAPDH DNA copy number (Figure
15). Figure 16 shows also the average of the HMTV/GAPDH DNA
copy number ratio (A) for DCIS and IDC of 7 samples. There was a
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dramatic decrease in HMTV copy number between the two stages
with a statistical significance of p-value= 0.01. RT PCR was con-
ducted also on DNA extracted from NEC, DCIS and IDC from two
different patients (Figure15). In each patient PCR was positive in
NEC and DCIS, whereas negative in IDC. In both patients there is
an increase in HMTV DNA copy number after the progression from
normal epithelium to DCIS, while there is a complete loss of the
virus in the invasive stage.
Figure 15: RT-PCR conducted on genomic DNA extracted from
cells of different nature in two different patients: normal cells coll
teral to carcinoma, DCIS and IDC three histological stages (normal
ducts, DCIS and IDC). Bars represent the relative HMTV DNA
copy number to GAPDH DNA copy number used as an internal
gene reference control.
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Figure 16: RT-PCR conducted on genomic DNA extracted from
seven samples of two histological stages of cancer, DCIS and IDC.
Bars represent an average of all HMTV DNA / GAPDH DNA ra-
tios. Difference is highly significant, with a p-value of 0.01.
Chromogen in situ hybridization (CISH)
We have designed homemade probe to investigate the presence of
HMTV sequence in the tumor cells under the light microscope.
The idea behind doing CISH on our samples mainly DCIS and IDC
is a further confirmation of our results. CISH is very specific tech-
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niques that detect the viral sequence in the nucleus of infected cells
as coloured dots.
Fluorescent nested PCR and Real time PCR have showed higher
expression of HMTV sequences in DCIS compared to IDC. These
results are further confirmed by CISH that showed higher number
of infected cells with HMTV in DCIS compared to IDC (figure 17).
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The frequency of HMTV in metastatic lymph nodes
The presence and the frequency of exogenous HMTV env-like
sequence in primary breast tumor, metastatic lymph nodes, and their
lymphocytes as well as in non metastatic lymph nodes are described
below and reported in Table 3.
Primary breast cancer (DCIS+ IDC) that do not develop metastasis
expressed exogenous HMTV env sequences in 11 out of 22 cases
(50%),whereas primary breast cancer that develop metastasis sowed
exogenous HMTV env positivity in 16 out of 23 cases (69.5%).
Furthermore we have also studied the presence of exogenous
HMTV in metastatic breast cancer cells which microdissected from
lymph nodes in order to compare the exogenous HMTV env status
in primary and their respective metastatic breast cancer cells. The
result was very similar as we detected the exogenous HMTV env in
11 out of 19 cases (68.4%) compared to 69.5% in their primary
breast cancer. In a try to study the HMTV status in lymphocytes we
have microdissected lymphocytes from lymph nodes which invaded
by primary breast cancer cells, and the exogenous HMTV env was
detected in 11 out of 19 (57.8%) comparing to 36% (8 out of 22) in
lymphocytes from lymph node that do not develop any metastasis.
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Tissue Cases HMTV env
positivity
%
Primary breast cancer (DCIS+ IDC) that do
not develop metastasis
22 11 50
Primary breast cancer(DCIS+ IDC) that
develop metastasis
23 16 69.5
Metastatic breast tumor in lymph nodes 19 13 68.4
Lymphocytes of metastatic lymph nodes 19 11 57.8
Non metastatic lymph nodes 22 8 36
Table 3: Number of HMTV positivity in different breast cancer
progressions.
The frequency of HMTV in primary and metastatic breast
cancer
The frequency of exogenous HMTV env sequence in metastasis of
breast cancer compared to their primary tumor was investigated for
a possible correlation between the presences of exogenous HMTV
env sequence in the primary and their respective metastatic breast
cancer (figure 18). We have detected the exogenous HMTV env
sequence in both primary and their
cer cells in 13 out 23
cancer were negative for
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The frequency of HMTV in primary breast cancers and
their lymph nodes
The presence and the frequency of exogenous HMTV env-like
sequence in primary breast cancer and in their non metastatic
lymph nodes, as well as in the primary breast cancer and in the
lymphocytes of their metastatic lymph nodes are described below
and reported in Figure 19, 20.
The exogenous HMTV env sequence was detected in 10 out of 19
(52.6%) cases of primary breast cancer and in the lymphocytes of
their metastatic lymph nodes. It has been shown that only two cases
were positive for exogenous HMTV env sequence of the primary
breast cancer cells but negative in the lymphocytes of their
metastatic lymph nodes, while only one case harbor the viral
sequence in the lymphocytes of their metastatic lymph nodes but
not in their respective primary tumor (figure 18). On the other hand,
the presence of exogenous HMTV env sequence was detected in 5
out 22 of cases (22.7%) of primary breast cancer and the lympho-
cytes of their respective lymph nodes. Exogenous HMTV env was
detected in 8 cases of the primary breast cancer but not in the lym-
phocytes of their metastatic lymph nodes, while 3 cases showed
positivity in the non metastatic lymph nodes, but not in the primary
breast cancer (figure 20).
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Tissue culture
Primary culture of human breast cancer
We have created primary cell line that has been grown for more
than a month. Breast cancer tissue was subjected to mechanical dis-
ruption followed by enzymatic treatment that resulted in the release
of breast organoids (clumps of tissue). Further enzymatic digestion
of the organoids yielded single cells that were seeded in low-
attachment plates (6 wells plate) in media devoid of serum (see Ma-
terials and Methods). Floating spheroids, termed mammospheres,
were observed within 5–7 days (figure 20). Cells obtained by the
enzymatic dissociation of mammospheres at each passage were fur-
ther seeded under culture conditions that allow cell attachment us-
ing primary cell culture flasks (figure 21). New additives to media
such as B27 sustain the growth of mammary tumor cells for long
period (more than a month).
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Presence of HMTV in primary culture of human breast
cancer
We have checked the primary breast cancer cell line that we have
created for the presence of exogenous HMTV env sequence.
Exogenous HMTV env sequence was detected in both DNA and
cDNA extracted from cells of primary culture that was monitored
by a fluorescent nested PCR assay which targeted 248 bp of env
sequence.
Infected cells were treated with 106 M dexamethasone (DEX) a po-
tent synthetic member of the glucocorticoid class of steroid drug
that increase spreading of MMTV in cultured human breast
cells[92].
Two weeks after applying of DEX, the DNA from these cells was
subjected to the HMTV-specific PCR analysis. Stronger PCR sig-
nals were detected at later cultivation time points (Figure 22).
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Figure 22 Quantification of viral RNA in cell lysates of human
breast cells in the presence and absence of 106 M DEX.
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DISCUSSION
Breast cancer evolves from atypical ductal hyperplasia, to carcino-
ma in situ, then invasive carcinoma, and finally distant metastasis,
which is usually the cause of death [108, 109]
The etiology of the sporadic breast carcinoma is unknown, with the
exception of the rare radiation induced neoplasms [110]. Since
many years the promoting role of estrogens is well established, but
a sound evidence of their possible causative action has not been
reached yet [111]
The molecular approach to breast cancer pathogenesis clearly dem-
onstrates that the classic distinction in ductal and lobular carcinoma
is giving place to a new terminology based on bio-molecular char-
acteristics [112-114].The provisory molecular classification in use
is clarifying that the group of “ductal carcinoma”, accounting for
about 80% of all types of breast carcinoma, contains an unpredict-
able number of different molecular subtypes. This molecular het-
erogeneity could be consequence of different causative agents or of
different transforming pathways caused by the same agent. In syn-
thesis: no etiological factor has been identified for sporadic breast
cancer; it is possible that different factors exist; it is also possible
that one or a few factors can give origin to the many molecular
pathways of breast carcinoma by using different transforming
mechanisms.
A possible viral etiology is receiving today more consideration
than in the past, mainly because the demonstration of the causative
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role of HPV for the carcinoma of the cervix [115] has opened this
new frontier, but also because of the not rare papers demonstrating
the presence of exogenous MMTV sequences in infiltrating human
tumours[37-39] . The amount of information towards a possible ex-
istence of a human MTV accumulated during several decades is
impressive: a) viral particles in milk and in tumor tissues[19, 20, 38,
116] b) reverse transcriptase in milk[117], c) MMTV antigens in
serum and in tumors [118], d) epidemiological observation that hu-
man breast cancer incidence is higher in geographic areas
where Mus domesticus is the most prevalent mouse species[119], d)
association between breast cancer and lymphoma[120], e) occur-
rence of breast cancer in husbands and wives [121, 122], and f) fi-
nally the presence of exogenous MMTV sequences in a percentage
of 30-40% of human breast carcinomas[30, 37]. Interestingly, a
very recent paper shows a higher expression of Wnt1 protein in
human DCIS and IDC positive for MMTV [123].
Unfortunately, none of these data, alone or combined, is sufficient
to demonstrate that the most common cancer in women is given by
MMTV. On the other hand, there is no element clearly against this
hypothesis, whereas quantity and quality of data encourage pro-
ceeding in exploring this possibility.
For what concerns MMTV env-like, it seems clear that some nega-
tive results were consequence of the low quantity of env sequences
or of technical and methodological problems. A recent paper from
this laboratory demonstrates that a correct approach can avoid these
limitations [37]; in particular, a laser microdissection procedure to
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obtain a pure and enriched population of tumor cells and a highly
sensitive FN-PCR to have limited steps in DNA analysis. On the
basis of all the data present in the literature, it is reasonable to con-
clude that the presence of exogenous sequences of MMTV in infil-
trating human breast carcinoma is real and that the percentage of
positive cases is between 30 and 40%.
If MMTV env like is involved in human breast carcinogenesis, it
could play an early, an intermediate or a late role. On other words,
it could behave as a transforming agent, an etiological cofactor, and
a pathogenetic agent. Establishing when exogenous viral sequences
appear during the natural history of the disease would represent an
interesting contribution to answer the previous question. This work
investigates for the first time the presence of HMTV env in preinva-
sive lesions, as well as in infiltrating carcinomas and in normal tis-
sues. HMTV exogenous viral sequences are absent in UDH,
whereas present in 27% of AH, in 79.6% of DCIS and in 35% of
IDC. Normal epithelium collateral to DCIS is positive in 19% of
cases; whereas it is always negative when obtained from healthy
women undergo reduction mammoplasty.
These data seem well in line with the model of progression usually
accepted for breast cancer: normal epithelium, UDH, AH, DCIS,
IDC [124-129]. AH and DCIS are considered obliged precursor of
IDC; AH and low grade DCIS are now included in the same cate-
gory of DIN1, Ductal Intraepithelial Neoplasia. Usual type epithe-
lial hyperplasia represents a common finding in human breast, be-
ing expression of a hormonal de-rearrangement. In facts, it is con-
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sidered not related to cancerogenesis, as shown by its substantial
polyclonality and absence of chromosomal alterations and also by
the absence of dysregulation in adhesion and extracellular matrix
pathways. However, there are a small proportion of cases which are
monoclonal (3%), with the occurrence of LOH up to 15% of cases,
with few chromosomal aberrations. Normal epithelium can show
molecular alterations similar to those occurring in cancer, mainly in
areas close to an invasive carcinoma, as expected by the hypothesis
of “field cancerogenesis” occurring in breast as in other organs. In
summary, the few epithelial cells transformed by the unknown can-
cerogenetic agent in a normal looking breast glandular structure,
under the proliferative stimulus of estrogens can give origin to
small neoplastic clones in a small number of UDH, which is a very
frequent benign alteration. The subsequent expansion of the neo-
plastic clones, with the accumulation of genomic aberrations, gives
origin to AH, where nuclear atypia is easily evident.
Exogenous HMTV env sequences are present in normal epithelium
close to IDC in a small percentage of cases and have not been found
in normal epithelium of normal breast tissue obtained by reduction
mammoplasty and in UDH not associated to IDC. Their frequency
is well represented in AH, then increases dramatically in IDC and
goes back to a however well consistent value in IDC, similar to that
of AH.
The presence of HMTV env not only in IDC, but also in normal
breast, AH and DCIS demonstrates that these exogenous sequences
represent an event bound to early steps of cancerogenesis. The per-
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centage of 35% of positivity in IDC is expected on the basis of pre-
vious data. The absence of positivity in normal breast not associated
to cancer, the low number of positive cases in normal glandular
structures close to IDC and the absence of positivity in UDH are in
line with the field cancerogenesis model and with the biology of
UDH. The only apparently controversial result is the very high fre-
quency of HMTV env sequences in DCIS, of about 80%, with a
percentage of less than half in the two lesions immediately up-
stream and downstream, AH and IDC.
However, on the basis of the high level of technological accuracy
and the robust controls, there is no reason to doubt it. A possible
explanation for the strong decrease in positive cases moving from
DCIS to IDC can be that HMTV env sequences are relevant for
transformation, but less important for the transition DCIS-IDC.
Moreover, HMTV env sequences could be lost as consequence of
the high level of chromosomal rearrangement characterizing IDC. A
selective depletion of tumor cells expressing HMTV antigens can
also be assumed, as consequence of their identification and elimina-
tion by the immune system. These data are supported by results ob-
tained by RT-PCR, demonstrating that the HMTV env sequence
copy number is quite small and that there is a dramatic reduction
moving from DCIS to IDC. In addition, the copy number increases
from normal cells to DCIS. Furthermore, we have used another
supportive technique that further confirmed the results obtained by
PCR techniques; CISH, demonstrating that HMTV env sequence is
integrated in breast cancer cells but not in adenocarcinoma of colon
87
or normal cells of the breast, and showed higher number of DCIS
cells harbouring HMTV env sequence comparing to IDC.
Furthermore, a secondary but not negligible result of this study is
the demonstration that HMTV env sequence can be easily detected
in formalin fixed and paraffin embedded tissues.
Exogenous HMTV env sequences are detected in 50% of primary
breast cancer (DCIS and IDC) cases that do not developed metas-
tatic tumor. On the other hand, the primary tumor that developed
metastases were HMTV positive in 69.5%, and 68.4% in their cor-
responding metastatic tumor. A possible explanation for the higher
number of HMTV positive cases in metastatic tumor is that HMTV
first integrated the tumorigenic cells (cancer stem cell) , some of
them escape the immune system and develop metastasis. Moreover,
HMTV was positive in two cases of metastatic breast cancer and
negative in their primary cancer, this probably due to the fact that
the immune system negatively selected the virally infected tumor
cells, while some of them escape the immune system and develop
metastasis. The presence of HMTV env sequence in the lympho-
cytes of metastatic and non metastatic breast cancer may be consid-
ered as HMTV reservoir and rout of transmission.
HMTV viral particles were isolated from peritoneal fluid of patient
with metastatic breast cancer whose primary breast cancer was posi-
tive to HMTV env sequences[38]. We have succeeded in creating
primary breast cancer cell line that was positive for HMTV env se-
quence. Moreover, the expression of HMTV was increased after
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treating the cells with Dexamethasone, that has been shown to in-
fect human mammary cell line after incubated with MMTV positive
murine cell line [92]. The prospective study of this project will
focus on tissue culture and isolates the viral particles, as well as
studying the transforming ability of the virus.
In conclusion, exogenous HMTV env sequences are easily identifi-
able in the early steps of breast cancer progression, suggesting their
possible role in the transformation process, at least as etiological
co-factor. On the other hand, the strong reduction of positive cases
moving from DCIS to IDC suggests that they are not relevant for
the progression of the disease. Our data are sufficient to support the
hypothesis the HMTV env exogenous sequences are related to spo-
radic breast cancer progression.
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